Alzamend Neuro Inc Cash Flow Conversion Efficiency
Alzamend Neuro Inc cash flow conversion efficiency. Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has a cash flow conversion efficiency ratio of -0.196x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($5.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alzamend Neuro Inc (2016–2026)
Cash flow conversion efficiency of Alzamend Neuro Inc from 2016 to 2026. This chart illustrates how Alzamend Neuro Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alzamend Neuro Inc (ALZN) stock price for real-time trading data and today's change.
Alzamend Neuro Inc Cash Flow Conversion Ratio Explained
Alzamend Neuro Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alzamend Neuro Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alzamend Neuro Inc ranked by their cash flow conversion efficiency. Also see Alzamend Neuro Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc
LSE:ATR
|
0.005x |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
0.103x |
|
MSCM Holdings Bhd
KLSE:0041
|
-0.048x |
|
Skyline Investment S.A.
WAR:SKL
|
-0.002x |
|
FUXING CHINA GRP SD 5
F:3FU1
|
N/A |
|
JX Luxventure Limited
NASDAQ:JXG
|
-0.058x |
|
La Savonnerie de Nyons SA
PA:MLSDN
|
N/A |
|
Bt Brands Inc
NASDAQ:BTBD
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Alzamend Neuro Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of Alzamend Neuro Inc from 2016 to 2026. Review financial flexibility index of Alzamend Neuro Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | $733.21K | $-8.07 Million | -11.003x | -564.78% |
| 2025-04-30 | $3.97 Million | $-6.57 Million | -1.655x | -151.92% |
| 2024-04-30 | $-2.59 Million | $-8.27 Million | 3.188x | +208.80% |
| 2023-04-30 | $3.05 Million | $-8.92 Million | -2.930x | -491.46% |
| 2022-04-30 | $13.35 Million | $-6.61 Million | -0.495x | +63.23% |
| 2021-04-30 | $2.01 Million | $-2.71 Million | -1.347x | +52.81% |
| 2020-04-30 | $821.71K | $-2.35 Million | -2.855x | +13.44% |
| 2019-04-30 | $316.92K | $-1.05 Million | -3.298x | -272.82% |
| 2018-04-30 | $2.32 Million | $-2.05 Million | -0.885x | -136.52% |
| 2017-04-30 | $-584.93K | $-1.42 Million | 2.422x | -98.61% |
| 2016-04-30 | $-106.00 | $-18.49K | 174.453x | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, … Read more